AUSTAR FBDGC20 Multifunctional Fluid Bed Completes Site Acceptance at National Academy of Sciences in CIS Region!

Recently, AUSTAR Group successfully concluded the Site Acceptance Testing (SAT) for its FBDGC20 multifunctional fluidized bed system delivered to the Institute of Physical Organic Chemistry at the National Academy of Sciences in CIS Region, marking its official entry into scientific research applications. This delivery represents another milestone in AUSTAR's pharmaceutical equipment advancements across CIS countries.

As a next-generation intelligent pharmaceutical system, the FBDGC20 integrates three core functions: drying, top-spray granulation, and bottom-spray coating. Its modular design enables flexible working volume adjustments: 1-16L capacity (with interchangeable bowls) for drying and top-spray granulation, and 0.5-8.5L capacity (with interchangeable bowls) for bottom-spray coating, meeting diverse needs from lab-scale R&D to pilot production. The specially configured near-infrared (NIR) PAT probe system enhances process efficiency by approximately 70% compared to traditional offline testing through real-time moisture monitoring, providing precise data support for pharmaceutical formulation studies.

During the three-day SAT, local technical teams conducted comprehensive validation tests. Operational data demonstrated ±1.0°C temperature control accuracy and ±5% airflow stability during continuous 8-hour granulation, drying, and coating processes, with all critical parameters exceeding contractual requirements. Institute researchers noted: "The system's integrated multi-process capabilities and real-time monitoring features will significantly enhance our research efficiency in sustained-release formulations and pellet coating technologies."

This delivery aligns with the country's ongoing "National Pharma 2025" strategic initiatives. As the country's central hub for drug development, the Institute of Physical Organic Chemistry plans to leverage FBDGC20's technical advantages in its novel oral solid dosage form development platform to accelerate industrial-scale research on cardiovascular medications.